非维生素K拮抗剂口服抗凝药对心房颤动射频消融术中活化凝血时间达标的影响

目的 研究非维生素K拮抗剂口服抗凝药(NOAC)对心房颤动(简称房颤)射频消融术中活化凝血时间(ACT)的影响,为制定更优的肝素负荷方案,提高ACT达标率提供一定依据。方法 按入选排除标准纳入自2019年10月至2021年11月在徐州医科大学附属医院心内科行射频消融术的房颤患者。术前抗凝方案为达比加群酯(110 mg, 2次/天)、利伐沙班(15 mg, 1次/天)。患者均给予100U/Kg首剂肝素,在肝素给药前及初始肝素给药后30min(30min-ACT)及其后每30min测定ACT值。按30min-ACT分为：达标组(ACT≥250 s),未达标组(ACT<250 s)。按基础ACT分为基础ACT≤145 s; 145 s相似文献   

持续性心房颤动射频消融术中不同抗凝方案与围术期血栓事件的关系

目的探讨持续性心房颤动（房颤）患者经导管射频消融术中不同抗凝方案与围术期血栓事件的关系。方法2004年7月至2007年10月连续收治行导管射频消融治疗的持续性房颤145例。所有患者术前均口服华法林抗凝,使国际标准化比率（INR）控制在2．0—3．0至少1个月。消融前停用华法林并用低分子肝素替代抗凝。2004年7月至2006年1月消融的患者（组Ⅰ）64例,完成房间隔穿刺后,静脉给予普通肝素5000U;2006年2月至2007年10月消融的患者（组Ⅱ）81例,完成房间隔穿刺后根据患者体重予以肝素（100U／kg）,两组患者消融术中每小时均追加肝素1000U。消融后行低分子肝素抗凝3d并口服华法林治疗至少3个月。结果组Ⅰ有4例患者于围术期出现血栓形成或血栓栓塞;组Ⅱ1例持续性房颤患者因消融后第3天自行停用华法林出现短暂性脑缺血发作,其余严格抗凝的患者均未出现血栓事件。组Ⅰ与组Ⅱ消融术前后达到抗凝要求的持续性房颤患者血栓事件发生率差异有统计学意义（4／64对0／80,P=0．037）。结论消融中根据患者体重调整抗凝强度可以显著减少持续性房颤患者围术期血栓事件并发症的发生。     

持续性心房颤动射频消融术中不同抗凝方案与围术期血栓事件的关系

Objective The relationships between different anticoagulation methods during radiofre-quency catheter ablation(RFCA) of persistent/permanent atrial fibrillation (AF)and thromboembolic events in our center were evaluated. Methods From July 2004 to October 2007, RFCA was consecutively performed in 145 persistent/permanent AF patients. Anticoagulation with warfarin was administrated in all patients before op-eration for at least 1 month, with the international normalized ratio(INR) maintained between 2.0 and 3.0. Be-fore procedure,warfarin was discontinued and replaced by low molecular weight heparin(LMWH). After atrial septum puncture,a total of 5000 U tmfractioned heparin(UFH) were given to patients of group Ⅰ who under-went the ablation from July 2004 to January 2006,while patients of group Ⅱ who underwent the ablation from February 2006 to October 2007 were heparinized(100 U/Kg) according to their weights. During operation, 1000 U UFH was appended per hour. After procedure, LMWH was used for 3 days while warfarin was initiated at the same time and continued for at least 3 months. Results Four patients in group Ⅰ (64 patients ,51 men)experi-enced thrombosis or embolism during or after ablation. One female persistent AF patient in the group Ⅱ (81 pa-tients,67 men)who didn' t fulfill the anticoagulatian therapy experienced TIA after ablation. No thrombeembolic event was identified in other patients of group Ⅱ who fulfilled the anticoagulation therapy. The incidence of thromboembolic event of persistent/permanent AF patients who fulfilled the anticoagulation therapy in the group Ⅱwas lower than that of group Ⅰ (4/64 vs. 0/80, P = 0.037). Conclusions Strengthen the anticoagulation therapy according to patients' weights during radiofrequency ablation could significantly decrease the incidence of thromboembolic event in patients with persistent/permanent AF.     

持续性心房颤动射频消融术中不同抗凝方案与围术期血栓事件的关系

Objective The relationships between different anticoagulation methods during radiofre-quency catheter ablation(RFCA) of persistent/permanent atrial fibrillation (AF)and thromboembolic events in our center were evaluated. Methods From July 2004 to October 2007, RFCA was consecutively performed in 145 persistent/permanent AF patients. Anticoagulation with warfarin was administrated in all patients before op-eration for at least 1 month, with the international normalized ratio(INR) maintained between 2.0 and 3.0. Be-fore procedure,warfarin was discontinued and replaced by low molecular weight heparin(LMWH). After atrial septum puncture,a total of 5000 U tmfractioned heparin(UFH) were given to patients of group Ⅰ who under-went the ablation from July 2004 to January 2006,while patients of group Ⅱ who underwent the ablation from February 2006 to October 2007 were heparinized(100 U/Kg) according to their weights. During operation, 1000 U UFH was appended per hour. After procedure, LMWH was used for 3 days while warfarin was initiated at the same time and continued for at least 3 months. Results Four patients in group Ⅰ (64 patients ,51 men)experi-enced thrombosis or embolism during or after ablation. One female persistent AF patient in the group Ⅱ (81 pa-tients,67 men)who didn' t fulfill the anticoagulatian therapy experienced TIA after ablation. No thrombeembolic event was identified in other patients of group Ⅱ who fulfilled the anticoagulation therapy. The incidence of thromboembolic event of persistent/permanent AF patients who fulfilled the anticoagulation therapy in the group Ⅱwas lower than that of group Ⅰ (4/64 vs. 0/80, P = 0.037). Conclusions Strengthen the anticoagulation therapy according to patients' weights during radiofrequency ablation could significantly decrease the incidence of thromboembolic event in patients with persistent/permanent AF.     

持续性心房颤动射频消融术中不同抗凝方案与围术期血栓事件的关系

Objective The relationships between different anticoagulation methods during radiofre-quency catheter ablation(RFCA) of persistent/permanent atrial fibrillation (AF)and thromboembolic events in our center were evaluated. Methods From July 2004 to October 2007, RFCA was consecutively performed in 145 persistent/permanent AF patients. Anticoagulation with warfarin was administrated in all patients before op-eration for at least 1 month, with the international normalized ratio(INR) maintained between 2.0 and 3.0. Be-fore procedure,warfarin was discontinued and replaced by low molecular weight heparin(LMWH). After atrial septum puncture,a total of 5000 U tmfractioned heparin(UFH) were given to patients of group Ⅰ who under-went the ablation from July 2004 to January 2006,while patients of group Ⅱ who underwent the ablation from February 2006 to October 2007 were heparinized(100 U/Kg) according to their weights. During operation, 1000 U UFH was appended per hour. After procedure, LMWH was used for 3 days while warfarin was initiated at the same time and continued for at least 3 months. Results Four patients in group Ⅰ (64 patients ,51 men)experi-enced thrombosis or embolism during or after ablation. One female persistent AF patient in the group Ⅱ (81 pa-tients,67 men)who didn' t fulfill the anticoagulatian therapy experienced TIA after ablation. No thrombeembolic event was identified in other patients of group Ⅱ who fulfilled the anticoagulation therapy. The incidence of thromboembolic event of persistent/permanent AF patients who fulfilled the anticoagulation therapy in the group Ⅱwas lower than that of group Ⅰ (4/64 vs. 0/80, P = 0.037). Conclusions Strengthen the anticoagulation therapy according to patients' weights during radiofrequency ablation could significantly decrease the incidence of thromboembolic event in patients with persistent/permanent AF.     

持续性心房颤动射频消融术中不同抗凝方案与围术期血栓事件的关系

Objective The relationships between different anticoagulation methods during radiofre-quency catheter ablation(RFCA) of persistent/permanent atrial fibrillation (AF)and thromboembolic events in our center were evaluated. Methods From July 2004 to October 2007, RFCA was consecutively performed in 145 persistent/permanent AF patients. Anticoagulation with warfarin was administrated in all patients before op-eration for at least 1 month, with the international normalized ratio(INR) maintained between 2.0 and 3.0. Be-fore procedure,warfarin was discontinued and replaced by low molecular weight heparin(LMWH). After atrial septum puncture,a total of 5000 U tmfractioned heparin(UFH) were given to patients of group Ⅰ who under-went the ablation from July 2004 to January 2006,while patients of group Ⅱ who underwent the ablation from February 2006 to October 2007 were heparinized(100 U/Kg) according to their weights. During operation, 1000 U UFH was appended per hour. After procedure, LMWH was used for 3 days while warfarin was initiated at the same time and continued for at least 3 months. Results Four patients in group Ⅰ (64 patients ,51 men)experi-enced thrombosis or embolism during or after ablation. One female persistent AF patient in the group Ⅱ (81 pa-tients,67 men)who didn' t fulfill the anticoagulatian therapy experienced TIA after ablation. No thrombeembolic event was identified in other patients of group Ⅱ who fulfilled the anticoagulation therapy. The incidence of thromboembolic event of persistent/permanent AF patients who fulfilled the anticoagulation therapy in the group Ⅱwas lower than that of group Ⅰ (4/64 vs. 0/80, P = 0.037). Conclusions Strengthen the anticoagulation therapy according to patients' weights during radiofrequency ablation could significantly decrease the incidence of thromboembolic event in patients with persistent/permanent AF.     

持续性心房颤动射频消融术中不同抗凝方案与围术期血栓事件的关系

Objective The relationships between different anticoagulation methods during radiofre-quency catheter ablation(RFCA) of persistent/permanent atrial fibrillation (AF)and thromboembolic events in our center were evaluated. Methods From July 2004 to October 2007, RFCA was consecutively performed in 145 persistent/permanent AF patients. Anticoagulation with warfarin was administrated in all patients before op-eration for at least 1 month, with the international normalized ratio(INR) maintained between 2.0 and 3.0. Be-fore procedure,warfarin was discontinued and replaced by low molecular weight heparin(LMWH). After atrial septum puncture,a total of 5000 U tmfractioned heparin(UFH) were given to patients of group Ⅰ who under-went the ablation from July 2004 to January 2006,while patients of group Ⅱ who underwent the ablation from February 2006 to October 2007 were heparinized(100 U/Kg) according to their weights. During operation, 1000 U UFH was appended per hour. After procedure, LMWH was used for 3 days while warfarin was initiated at the same time and continued for at least 3 months. Results Four patients in group Ⅰ (64 patients ,51 men)experi-enced thrombosis or embolism during or after ablation. One female persistent AF patient in the group Ⅱ (81 pa-tients,67 men)who didn' t fulfill the anticoagulatian therapy experienced TIA after ablation. No thrombeembolic event was identified in other patients of group Ⅱ who fulfilled the anticoagulation therapy. The incidence of thromboembolic event of persistent/permanent AF patients who fulfilled the anticoagulation therapy in the group Ⅱwas lower than that of group Ⅰ (4/64 vs. 0/80, P = 0.037). Conclusions Strengthen the anticoagulation therapy according to patients' weights during radiofrequency ablation could significantly decrease the incidence of thromboembolic event in patients with persistent/permanent AF.     

持续性心房颤动射频消融术中不同抗凝方案与围术期血栓事件的关系

Objective The relationships between different anticoagulation methods during radiofre-quency catheter ablation(RFCA) of persistent/permanent atrial fibrillation (AF)and thromboembolic events in our center were evaluated. Methods From July 2004 to October 2007, RFCA was consecutively performed in 145 persistent/permanent AF patients. Anticoagulation with warfarin was administrated in all patients before op-eration for at least 1 month, with the international normalized ratio(INR) maintained between 2.0 and 3.0. Be-fore procedure,warfarin was discontinued and replaced by low molecular weight heparin(LMWH). After atrial septum puncture,a total of 5000 U tmfractioned heparin(UFH) were given to patients of group Ⅰ who under-went the ablation from July 2004 to January 2006,while patients of group Ⅱ who underwent the ablation from February 2006 to October 2007 were heparinized(100 U/Kg) according to their weights. During operation, 1000 U UFH was appended per hour. After procedure, LMWH was used for 3 days while warfarin was initiated at the same time and continued for at least 3 months. Results Four patients in group Ⅰ (64 patients ,51 men)experi-enced thrombosis or embolism during or after ablation. One female persistent AF patient in the group Ⅱ (81 pa-tients,67 men)who didn' t fulfill the anticoagulatian therapy experienced TIA after ablation. No thrombeembolic event was identified in other patients of group Ⅱ who fulfilled the anticoagulation therapy. The incidence of thromboembolic event of persistent/permanent AF patients who fulfilled the anticoagulation therapy in the group Ⅱwas lower than that of group Ⅰ (4/64 vs. 0/80, P = 0.037). Conclusions Strengthen the anticoagulation therapy according to patients' weights during radiofrequency ablation could significantly decrease the incidence of thromboembolic event in patients with persistent/permanent AF.     

持续性心房颤动射频消融术中不同抗凝方案与围术期血栓事件的关系

Objective The relationships between different anticoagulation methods during radiofre-quency catheter ablation(RFCA) of persistent/permanent atrial fibrillation (AF)and thromboembolic events in our center were evaluated. Methods From July 2004 to October 2007, RFCA was consecutively performed in 145 persistent/permanent AF patients. Anticoagulation with warfarin was administrated in all patients before op-eration for at least 1 month, with the international normalized ratio(INR) maintained between 2.0 and 3.0. Be-fore procedure,warfarin was discontinued and replaced by low molecular weight heparin(LMWH). After atrial septum puncture,a total of 5000 U tmfractioned heparin(UFH) were given to patients of group Ⅰ who under-went the ablation from July 2004 to January 2006,while patients of group Ⅱ who underwent the ablation from February 2006 to October 2007 were heparinized(100 U/Kg) according to their weights. During operation, 1000 U UFH was appended per hour. After procedure, LMWH was used for 3 days while warfarin was initiated at the same time and continued for at least 3 months. Results Four patients in group Ⅰ (64 patients ,51 men)experi-enced thrombosis or embolism during or after ablation. One female persistent AF patient in the group Ⅱ (81 pa-tients,67 men)who didn' t fulfill the anticoagulatian therapy experienced TIA after ablation. No thrombeembolic event was identified in other patients of group Ⅱ who fulfilled the anticoagulation therapy. The incidence of thromboembolic event of persistent/permanent AF patients who fulfilled the anticoagulation therapy in the group Ⅱwas lower than that of group Ⅰ (4/64 vs. 0/80, P = 0.037). Conclusions Strengthen the anticoagulation therapy according to patients' weights during radiofrequency ablation could significantly decrease the incidence of thromboembolic event in patients with persistent/permanent AF.     

持续性心房颤动射频消融术中不同抗凝方案与围术期血栓事件的关系

Objective The relationships between different anticoagulation methods during radiofre-quency catheter ablation(RFCA) of persistent/permanent atrial fibrillation (AF)and thromboembolic events in our center were evaluated. Methods From July 2004 to October 2007, RFCA was consecutively performed in 145 persistent/permanent AF patients. Anticoagulation with warfarin was administrated in all patients before op-eration for at least 1 month, with the international normalized ratio(INR) maintained between 2.0 and 3.0. Be-fore procedure,warfarin was discontinued and replaced by low molecular weight heparin(LMWH). After atrial septum puncture,a total of 5000 U tmfractioned heparin(UFH) were given to patients of group Ⅰ who under-went the ablation from July 2004 to January 2006,while patients of group Ⅱ who underwent the ablation from February 2006 to October 2007 were heparinized(100 U/Kg) according to their weights. During operation, 1000 U UFH was appended per hour. After procedure, LMWH was used for 3 days while warfarin was initiated at the same time and continued for at least 3 months. Results Four patients in group Ⅰ (64 patients ,51 men)experi-enced thrombosis or embolism during or after ablation. One female persistent AF patient in the group Ⅱ (81 pa-tients,67 men)who didn' t fulfill the anticoagulatian therapy experienced TIA after ablation. No thrombeembolic event was identified in other patients of group Ⅱ who fulfilled the anticoagulation therapy. The incidence of thromboembolic event of persistent/permanent AF patients who fulfilled the anticoagulation therapy in the group Ⅱwas lower than that of group Ⅰ (4/64 vs. 0/80, P = 0.037). Conclusions Strengthen the anticoagulation therapy according to patients' weights during radiofrequency ablation could significantly decrease the incidence of thromboembolic event in patients with persistent/permanent AF.     

Early heparinization decreases the incidence of left atrial thrombi detected by intracardiac echocardiography during radiofrequency ablation for atrial fibrillation

INTRODUCTION: We reviewed our experience in managing intracardiac ultrasound-detected left atrial thrombus and analyzed the impact of the timing of heparin therapy on thrombus incidence. METHODS AND RESULTS: We identified 508 patients undergoing ablation procedures for atrial fibrillation in which intracardiac ultrasound was used. All patients received unfractionated heparin during the procedure: 31 patients before the first transseptal puncture (preTS1), 257 between the first and second transseptal punctures (TS1-TS2), and 220 following both punctures (postTS2). By using intracardiac echocardiography (ICE), thrombus was detected in 30 of these 508 patients (5.9%). Of these, 29 were in the left atrium and constituted our study group. In 21 patients, the thrombi were successfully aspirated from the left atrium using strong suction through the transseptal sheath. All patients in whom thrombi were aspirated did well without neurological event or death. When patients received heparin therapy either preTS1 or TS1-TS2, there was a significant decrease in the occurrence of ICE-detected left atrial thrombus compared with those who received heparin postTS2 (0 of 31 patients (0%) preTS, 9 of 257 (3.5%) TS1-TS2, and 20 of 220 (9.1%) postTS2; (preTS1 vs postTS2, p = 0.01; preTS2 [preTS1 and TS1-TS2] vs postTS2, p < 0.001). CONCLUSION: Early administration of intravenous heparin, specifically before transseptal puncture, decreases the incidence of left atrial thrombi.     

射频导管消融治疗青年人群心房颤动的临床分析

目的 对青年心房颤动（房颤）患者（≤45岁）接受三维标测系统指导下房颤射频导管消融治疗的临床疗效和安全性予以研究.方法 回顾分析兰州军区兰州总医院自2011年1月至2012年5月在EnSite 3000指导下接受房颤射频消融治疗的152例患者,按年龄分为青年房颤患者（≤45岁）和中老年房颤患者（＞45岁）,对比分析其在临床基线资料、消融术时间、X线曝光时间、住院天数、术后复发率、术后6个月服药率和并发症发生率等临床指标上的差异.结果 与中老年房颤患者（n=125）相比,青年房颤患者（n=27）多以阵发性房颤为主（P＜0.05）,且术前左心房内径较小（P＜0.01）,消融术时间明显缩短（P＜0.01）,术后住院天数减少（P＜0.01）,复发率和术后6个月服药率均明显减少（P＜0.05）.结论 青年房颤患者多以阵发性房颤为主且较少伴有高血压、糖尿病等疾病,接受房颤消融术后恢复较快且房颤复发率低.     

经导管线性消融术对左心房功能影响的研究

目的评价左心房线性消融术对心房颤动（房颤）患者左心房功能的影响。方法选择30例Carto系统标测指导下行左心房线性消融术的阵发性房颤患者，应用超声心动图测定其消融术前1～3d、术后3个月静息时窦性心律下左心房容积指标、二尖瓣口A波速度峰值（VA）及左心房射血力，分析消融术前后左心房功能的变化。结果消融术后反应左心房辅泵功能的指标左心房射血力、VA、左心房主动排空容积、左心房主动排空分数、左心房总排空分数显著下降，反应左心房管道功能的左心房管道容积增加，反应左心房储存功能的指标左心房总排空容积、左心房最大容积无明显变化。结论Carto系统标测下左心房线性消融术后左心房辅泵功能下降，管道功能增强，而储存功能无显著改变。     

心房颤动射频消融术后远程心电监测随访的意义

目的通过电话心电远程监测心房颤动（房颤）射频消融术后复发情况,探讨远程心电监测仪诊断心律失常的临床价值。方法自2009年10月至2010年4月在我院行房颤射频消融术患者72例,其中持续性房颤39例、阵发性房颤33例。患者在消融术后第1天及每3个月均接受24h动态心电图检查,同时术后每天定时及有症状时接受电话远程传输心电图（TTECG）监测。比较两种检测方法记录的房颤复发情况及房颤发生与症状的相关性。结果随访（11．0±2．3）个月,TTECG共检测到4403份无干扰心电图,3610份窦性心电图中有症状的1351份（37．43％）。793份异常心电图中无症状性发作的214份（26．99％）。术后3个月空白期中,24h动态心电图发现17例（23．61％）房颤复发,TrECG发现31例复发,差异有统计学意义（P=0．004）。随访期间,24h动态心电图发现9例房颤患者复发,TTECG发现18例复发,差异有统计学意义（P=0．033）。通过TTECG的监测,与空白期的复发率比较,1年后房颤复发率明显下降（P=0．022）,而24h动态心电图未发现复发率的差异（P=0．083）。通过24h动态心电图及TTECG监测,持续性房颤消融成功率分别为84．62％,71．79％（P=0．000）,阵发性房颤消融成功率分别为90．91％,78．79％（P=0．006）。结论对于心律失常尤其是射频消融术后房颤的监测,电话远程心电监测优于常规24h动态心电监测,能及时发现术后房性心律失常复发,尤其是无症状性房颤。术后有症状患者也不一定是真正的房颤复发,实际为窦性心律。     

经导管点状射频消融反复短阵"心房颤动"

目的　报道反复短阵快速房性心律失常的电生理特性、射频导管消融方法和结果。方法　对 32例自发的反复短阵快速房性心律失常患者进行射频导管消融。观察房性心律失常的心内激动顺序和周长。单极和双极标测快速房性心律失常的起源病灶 ,并进行消融。结果　 32例患者的快速房性心律失常的心电图表现酷似心房颤动。AA间期绝对不齐 16 0～ 4 5 0ms,平均 (2 87± 93)ms ,而心房激动顺序则绝对规整有序。局部点状消融成功治疗所有患者的房性心律失常。平均随访 (14± 8)个月 ,1例复发。结论　反复短阵快速房性心律失常是一种局灶性房性心动过速 ,而非心房颤动。点状消融可达到根治的目的。     

环单侧靶肺静脉-前庭射频消融治疗心房颤动

目的 Carto系统指导下对心房颤动（房颤）相关的靶肺静脉进行环同侧上、下肺静脉-前庭单环线性消融隔离,观察疗效.方法 对25例术中反复自发肺静脉相关房性早搏（房早）,并触发房性心动过速（房速）和/或房颤的患者,在Carto系统结合单Lasso环状标测导管指导下进行环靶肺静脉-前庭单环射频消融术,达到肺静脉隔离.结果 消融过程中25例患者房早、房速、房颤终止,其中19例患者有自发的肺静脉电位,15例慢于窦性心率.4例患者隔离后肺静脉内发生房颤或房速,2例在肺静脉内补点消融后肺静脉电位消失.随访（22.24±9.01）个月,23例无房速、房颤发作,2例患者术后复发房颤,1例接受再次手术,术后房颤发作减少,1例口服胺碘酮控制.结论 术中能够明确靶肺静脉、单个触发灶的房颤患者,在Carto系统结合单Lasso导管指导下行单环线性消融隔离治疗房颤,成功率高、复发率低,可减少手术损伤.     

环状标测电极指导下射频消融治疗阵发性房颤的临床分析

目的探讨环状标测电极指导下射频消融治疗阵发性心房颤动的疗效。方法对23例阵发性房颤患者在环状电极指示下行经验性肺静脉和（或）上腔静脉电隔离。结果23例阵发性房颤患者中共隔离肺加上腔静脉87条，左上肺静脉22条，左下肺静脉18条，右上肺静脉22条，右下肺静脉12条，上腔静脉13条，平均每例3．78条。平均操作时间和X线透视时间分别为（148±34）min和（52±9）min。1例发生术中心包填塞，2例行2次手术。平均随访（3．8±1．6）个月，20例无房颤复发，2例有房早发作，成功22例。结论阵发性心房颤动采用环状标测电极指导下射频消融电隔离术对绝大多数患者是有效的，并能改善患者的心功能情况。     

抗凝管理服务在心房颤动导管消融术后患者中的应用评价

目的 评价抗凝管理服务(AMS)在心房颤动(房颤)导管消融术后患者中的应用价值.方法 连续245例[男134例,年龄(64±11)岁]接受导管消融治疗的房颤患者,所有患者术后均接受口服华法林抗凝治疗3～6个月.其中,前116例随机就诊于心内科门诊并接受华法林剂量调整(非AMS组),后129例接受经过培训的专业护士指导下的华法林剂量调整(AMS组).比较两组的国际标准化比值(INR)达标率(INR值位于2.0～3.0之间)、有效抗凝率(≥70％的INR测定值达标)及INR波动指数(达标后的最大INR值-达标后最小INR值-1).结果 AMS组的INR达标率(92.2％)和有效抗凝率(59.8％)均显著高于非AMS组(分别为80.2％和42.7％,P值分别为0.008和0.027).AMS组的INR波动指数0.64±0.74显著小于非AMS组(1.01±1.03,P=0.004).结论 在房颤导管消融术后应用华法林抗凝治疗的患者中系统应用AMS有助于提高抗凝治疗的达标率和有效抗凝率,并减小INR值的波动性.     

个体化的心房消融终止心房颤动

目的心房颤动(房颤,AF)的发生和维持可能存在多种机制,对所有的AF都以一种固定的术式进行消融治疗缺乏针对性。为此,我们采用心内非接触式标测,探索个体化消融的可行性。方法52例患者(男性44例,女性8例),年龄22～70(51.1±10.9)岁,左心房内径22～54(36.1±6.5)mm,其中12例为持续性AF(1～22年)。均经房间隔穿刺在左心房内对AF进行非接触式等电位标测,并在等电位标测下逐步进行个体化消融,消融术式不固定,以AF被终止且不被诱发、消融线形成双向阻滞为消融终点。结果AF被分为3种类型,而肺静脉(pulmonaryvein,PV)口周围、左心房顶部是波阵面的主要传导区。消融方式根据标测结果决定,包括在以上任一部位的线性消融、环PV口外的线性消融等,其中持续性AF多形成绕PV口周的环形消融加左心房顶部消融线。82.7%(43/52)的AF被消融所终止且不能再诱发,其中4例需在右心房消融方成功;另有5例的AF被转变为左心房扑动(房扑)。首次消融的即时成功率为90.4%(47/52)。消融中1例有心脏压塞。6例首次消融后有左心房房扑的患者再次接受了消融,标测发现既往消融线存在缝隙,针对缝隙消融后心动过速均被终止且不能被诱发。平均随访(11.0±6.2)个月,术后3个月82.7%(43/52)的患者不服药物亦无AF发生,其中阵发性AF成功率为87.5%(35/40);持续性AF为66.7%(8/12),其余患者均转为左心房房扑。结论本组结果初步提示,在非接触式等电位标测的基础上进行个体化的心房电学改良消融可有效地终止AF并有较好的中期疗效。其远期的效果有待观察。